P01.168 International Inconsistency in management of recurrent glioblastoma creates challenges in developing new clinical trials

摘要

BackgroundThe optimal choice and timing of treatment for recurrent GBM is unclear. Understanding the effect of further treatment on survival and quality of life, compared with best supportive care, is a top 10 clinical priority for the UK neuro-oncology community. Prior to developing a clinical trial to address this uncertainty we surveyed the neuro-oncology community to understand current variations in practice.